Page last updated: 2024-12-05

1,4-butanediol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth

Description

1,4-Butanediol (BDO) is a colorless, viscous liquid with a sweet odor. It is a versatile chemical intermediate used in the production of a wide range of products, including polyesters, polyurethanes, and tetrahydrofuran (THF). BDO can be synthesized through various methods, including the hydroformylation of propylene, the Reppe reaction, and the fermentation of biomass. BDO is a valuable chemical intermediate due to its reactivity and versatility. It is used in the production of polymers, solvents, and other chemicals. The importance of BDO stems from its applications in various industries, including textiles, automotive, construction, and pharmaceuticals. Its properties, such as its high boiling point and its ability to form esters and ethers, make it suitable for these applications. BDO is studied extensively for its potential use in the production of bio-based chemicals, which could reduce reliance on fossil fuels. Researchers are investigating sustainable and environmentally friendly methods for producing BDO from renewable resources, such as biomass. BDO can be toxic if ingested or absorbed through the skin, and it may cause respiratory irritation. It is important to handle BDO with caution and follow appropriate safety procedures. '

butane-1,4-diol : A butanediol that is butane in which one hydrogen of each of the methyl groups is substituted by a hydroxy group. A colourless, water-miscible, viscous liquid at room temperature (m.p. 16degreeC) with a high boiling point (230degreeC), it is mainly used for the production of other organic chemicals, particularly the solvent oxolane (also known as tetrahydrofuran or THF). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8064
CHEMBL ID171623
CHEBI ID41189
MeSH IDM0118642

Synonyms (82)

Synonym
1,4-butanediol ,
bu1 ,
110-63-4
butane-1,4-diol
inchi=1/c4h10o2/c5-3-1-2-4-6/h5-6h,1-4h
nsc406696
sucol b
1,4-tetramethylene glycol
1,4-bd
nsc-406696
diol 14b
tetramethylene glycol
1,4-dihydroxybutane
1,4-butylene glycol
wln: q4q
NCGC00090733-01
brn 1633445
hsdb 1112
nsc 406696
ai3-07553
agrisynth b1d
einecs 203-786-5
ccris 5984
tetramethylene 1,4-diol
1,4-butanediol, reagentplus(r), 99%
DB01955
1,4-butanediol, reagentplus(r), >=99%
MLS001061198
smr000677930
BDO ,
AKOS000118735
chebi:41189 ,
CHEMBL171623
732189-03-6
NCGC00090733-02
hoch2ch2ch2ch2oh
ho(ch2)4oh
HMS3039N12
tox21_303040
NCGC00257119-01
dtxcid804666
cas-110-63-4
dtxsid2024666 ,
tox21_202245
NCGC00259794-01
B0680
STL283940
4-01-00-02515 (beilstein handbook reference)
ec 203-786-5
unii-7xoo2le6g3
7xoo2le6g3 ,
FT-0606811
1,4-butanediol [inci]
1,4-butanediol [mi]
1,4-butanediol [hsdb]
BP-21418
butan-1.4-diol
1.4 - butanediol
1,4-butane-diol
butane 1,4-diol
1,4butanediol
4-hydroxybutanol
1.4-butanediol
1,4- butandiol
1,4-butane diol
1,4-butandiol
butane-1-4-diol
J-503971
1,4 butylene glycol
dabco bdo
butane diol-1,4
mfcd00002968
J-512798
1,4-butanediol, 99%
F0001-0222
dabco dbo
1,4-butanediol, vetec(tm) reagent grade, 98%
1,4-butanediol, for synthesis, 98%
CS-W016669
Q161521
dihydroxybutane
F71206

Research Excerpts

Toxicity

1,4-butanediol and gamma-butyrolactone began to be marketed as dietary supplements. We identified nine episodes of toxic effects in eight patients who had ingested the supplement recreationally or to enhance bodybuilding.

ExcerptReferenceRelevance
" After reports of toxic effects of gamma-hydroxybutyrate and its resultant regulation by the federal government, 1,4-butanediol and gamma-butyrolactone, another precursor of gamma-hydroxybutyrate and an industrial solvent, began to be marketed as dietary supplements."( Adverse events, including death, associated with the use of 1,4-butanediol.
Hall, BJ; McCutcheon, JR; Peacock, EA; Smith, SW; Spillane, J; Zvosec, DL, 2001
)
0.76
"From June 1999 through December 1999, we identified cases of toxic effects of 1,4-butanediol involving patients who presented to our emergency departments with a clinical syndrome suggesting toxic effects of gamma-hydroxybutyrate and a history of ingesting 1,4-butanediol and patients discovered through public health officials and family members."( Adverse events, including death, associated with the use of 1,4-butanediol.
Hall, BJ; McCutcheon, JR; Peacock, EA; Smith, SW; Spillane, J; Zvosec, DL, 2001
)
0.78
"We identified nine episodes of toxic effects in eight patients who had ingested 1,4-butanediol recreationally, to enhance bodybuilding, or to treat depression or insomnia."( Adverse events, including death, associated with the use of 1,4-butanediol.
Hall, BJ; McCutcheon, JR; Peacock, EA; Smith, SW; Spillane, J; Zvosec, DL, 2001
)
0.78
" These include acute toxic effects, which may be fatal, and addiction and withdrawal."( Adverse events, including death, associated with the use of 1,4-butanediol.
Hall, BJ; McCutcheon, JR; Peacock, EA; Smith, SW; Spillane, J; Zvosec, DL, 2001
)
0.55
" Pretreatment with 4-MP increased the Toxic Dose-50 (TD(50)) of 1,4-BD for the righting reflex from 585 mg/kg (95% CI, 484-707 mg/kg) in control mice to 5,550 mg/kg (95% CI, 5,353-5,756 mg/kg) in pretreated mice."( Pretreatment of CD-1 mice with 4-methylpyrazole blocks toxicity from the gamma-hydroxybutyrate precursor, 1,4-butanediol.
Desai, MC; Maher, TJ; Quang, LS; Shannon, MW; Woolf, AD, 2002
)
0.53

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effects of liquid hot water combined with 1, 4-butanediol (LHW-BDO) on the chemical composition and structure of moso bamboo were investigated."( Effects of Liquid Hot Water Combined with 1, 4-Butanediol on Chemical Composition and Structure of Moso Bamboo.
Jiang, JC; Wei, M; Xie, JC; Xu, H; Yang, J; Zhang, N; Zhao, J, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" Here, we report dose-response and time-course analyses for effects of GBL and 1,4-BD on locomotor activity and body temperature in Swiss-Webster mice."( Comparison of the actions of gamma-butyrolactone and 1,4-butanediol in Swiss-Webster mice.
Coleman, SL; de Fiebre, CM; de Fiebre, NE; Forster, MJ, 2004
)
0.57
"In the dose-response experiments, the acute administration of 4-MP and SCH 50911 exerted a dose-dependent resuscitative effect in mice acutely intoxicated by 3 g/kg 1,4-BD."( Resuscitative treatments on 1,4-butanediol mortality in mice.
Carai, MA; Colombo, G; Gessa, GL; Maher, TJ; Quang, LS, 2006
)
0.63
" Baclofen shifted the flumazenil dose-response curve to the right and down, possibly involving perceptual masking of the discriminative stimulus effects of flumazenil by agonist activity at GABAB receptors."( Discriminative stimulus effects of flumazenil: perceptual masking by baclofen, and lack of substitution with gamma-hydroxybutyrate and its precursors 1,4-butanediol and gamma-butyrolactone.
Carter, LP; Coop, A; France, CP; Koek, W; Wu, H, 2006
)
0.53
" Pulse oximetry readings were lower 45 min after BD dosing with a mean oxygen saturation of 98."( Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers.
Dyer, JE; Haller, CA; Jacob, P; Thai, D, 2007
)
0.64
" Because of the unusually steep dose-response curves, accidental GHB overdosing, leading to coma, seizures or death can occur."( Determination of gamma-hydroxybutyrate (GHB) and its precursors in blood and urine samples: a salting-out approach.
Ariniemi, K; Kankaanpää, A; Liukkonen, R, 2007
)
0.34
" Dose-response functions determined with both training compounds revealed a clear dissociation between the discriminative stimulus effects of these drugs."( Differentiating the discriminative stimulus effects of gamma-hydroxybutyrate and ethanol in a three-choice drug discrimination procedure in rats.
Baker, LE; Poling, A; Pynnonen, DM; Searcy, GD, 2008
)
0.35
" Given that humans most commonly ingest both drugs orally, we examined the dose-response relationships for intragastrically administered GHB and BDL on MAP and heart rate in conscious rats using radiotelemetry."( Cardiovascular responses elicited by intragastric administration of BDL and GHB.
Hicks, AR; Varner, KJ, 2008
)
0.35
" Dosing was initiated at 100 mg/kg and increased by 100mg/kg/day to 400mg/kg."( Physical dependence on gamma-hydroxybutrate (GHB) prodrug 1,4-butanediol (1,4-BD): time course and severity of withdrawal in baboons.
Gibson, KM; Goodwin, AK; Weerts, EM, 2013
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
BioRepublic Skincare Firming Facelift Magic Moss Mask -- 0.85 fl ozBioRepublic SkincareBeauty & Personal Carebutylene glycol, 1,4-butanediol, ascorbyl palmitate, benzoic acid, cetearyl alcohol, cetyl palmitate, chlorphenesin, panthenol, hydroxyphenyl propamidobenzoic acid, beta-glucan, ethylhexylglycerin, glyceryl stearate, glycerin, linalool, magnolol, o-cymen-5-ol, phenoxyethanol, propylene glycol2024-11-29 10:47:42

Roles (3)

RoleDescription
neurotoxinA poison that interferes with the functions of the nervous system.
protic solventA polar solvent that is capable of acting as a hydron (proton) donor.
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
butanediolA member of the class of butanediols that is butane in which two of the hydrogens have been replaced by hydroxy groups.
glycolA diol in which the two hydroxy groups are on different carbon atoms, usually but not necessarily adjacent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
GABA metabolism (aka GHB)1128

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency56.23410.031637.5844354.8130AID743255
GLI family zinc finger 3Homo sapiens (human)Potency58.04180.000714.592883.7951AID1259369; AID1259392
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency27.30600.000657.913322,387.1992AID1259378
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency26.96300.003041.611522,387.1992AID1159552; AID1159555
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency6.85900.000323.4451159.6830AID743065
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1134605Oil-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID71720Binding affinity towards [3H]GHB binding site at 10 uM1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies.
AID1134606Et2O-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (227)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (6.17)18.7374
1990's15 (6.61)18.2507
2000's82 (36.12)29.6817
2010's92 (40.53)24.3611
2020's24 (10.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.83%)5.53%
Reviews21 (8.71%)6.00%
Case Studies16 (6.64%)4.05%
Observational0 (0.00%)0.25%
Other202 (83.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]